Cite
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
MLA
Wick, Antje, et al. “Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination with Standard Temozolomide-Based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma.” Investigational New Drugs, vol. 38, no. 5, Oct. 2020, pp. 1570–79. EBSCOhost, https://doi.org/10.1007/s10637-020-00910-9.
APA
Wick, A., Desjardins, A., Suarez, C., Forsyth, P., Gueorguieva, I., Burkholder, T., Cleverly, A. L., Estrem, S. T., Wang, S., Lahn, M. M., Guba, S. C., Capper, D., & Rodon, J. (2020). Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Investigational New Drugs, 38(5), 1570–1579. https://doi.org/10.1007/s10637-020-00910-9
Chicago
Wick, Antje, Annick Desjardins, Cristina Suarez, Peter Forsyth, Ivelina Gueorguieva, Tiana Burkholder, Ann Louise Cleverly, et al. 2020. “Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination with Standard Temozolomide-Based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma.” Investigational New Drugs 38 (5): 1570–79. doi:10.1007/s10637-020-00910-9.